stockportfolio.pro
Vir Biotechnology, Inc. (VIR)
Healthcare · Biotechnology · NasdaqGS
Vir Biotechnology, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.71M | $10.67M | $8.09M | $76.37M | $1.10B | $1.62B | $86.18M | $74.20M | $68.56M |
| Gross profit | — | — | — | — | $1.03B | $1.47B | $83.42M | $73.36M | $68.53M |
| Net income | $-69.85M | $-115.88M | $-174.68M | $-298.67M | $528.58M | $515.84M | $-615.06M | $-521.96M | $-437.99M |
| Net margin | -2579.5% | -1086.3% | -2159.0% | -391.1% | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
Source: Vir Biotechnology, Inc. SEC filings (10-K).
Explore 9 years of Vir Biotechnology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VIR in your portfolio →
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. — frequently asked questions
What is Vir Biotechnology, Inc.'s revenue?
Vir Biotechnology, Inc. (VIR) reported revenue of $68.56M for fiscal year 2025, down 7.6% from the prior year, according to its SEC filings.
Is Vir Biotechnology, Inc. profitable?
No — VIR reported a net loss of $-437.99M in fiscal 2025.
What is VIR's P/E ratio?
Vir Biotechnology, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Vir Biotechnology, Inc. growing?
VIR's revenue grew at roughly -2.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Vir Biotechnology, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.